Meeting
2018 ASCO Annual Meeting
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.
Authors
Ezra E.W. Cohen
Moores Cancer Center at UC San Diego Health, University of California, San Diego, La Jolla, CA
Ezra E.W. Cohen , Denis Soulieres , Christophe Le Tourneau , Jose Dinis , Lisa F. Licitra , Myung-Ju Ahn , Ainara Soria , Jean-Pascal H. Machiels , Nicolas Mach , Ranee Mehra , Barbara Burtness , Misoo C. Ellison , Jonathan D. Cheng , Diana Romana Chirovsky , Ramona F. Swaby , Kevin J. Harrington
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02252042
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6013)
DOI
10.1200/JCO.2018.36.15_suppl.6013
Abstract #
6013
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
First Author: Kevin J. Harrington
Poster
2019 ASCO Annual Meeting
A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
First Author: Merrill A. Biel
Poster
2018 ASCO Annual Meeting
Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
First Author: Nabil F. Saba
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
First Author: Robert L. Ferris